P

Pasi A. Jänne

Harvard University

ORCID: 0000-0002-7821-4928

Publishes on Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies. 2.4k papers and 127.5k citations.

PubIndex Score98Top 2%How it's scored

🌟#1 Current Senior Leader in HER2/EGFR in Cancer Research 🌟#1 Current Senior Leader in Lung Cancer Treatments and Mutations 🌟#2 Current Senior Leader in Cancer Mechanisms and Therapy 🌟#2 Current Senior Leader in Colorectal Cancer Treatments and Studies 🌟#7 Current Senior Leader in Cancer therapeutics and mechanisms

2.4kPublications

127.5kTotal Citations

#1in HER2/EGFR in Cancer Research

First publication: 1986First senior author: 2004

Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics Lung Cancer Research Studies Colorectal Cancer Treatments and Studies HER2/EGFR in Cancer Research

Top publicationsby citations

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Matthew Meyerson, Pasi A. Jänne et al.|Science|2004

Cited by 9.4k

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Science|2007

Cited by 4.5k

The landscape of somatic copy-number alteration across human cancers

Rameen Beroukhim, Anthony Letai, Craig H. Mermel et al.|Nature|2010

Cited by 4.1k

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Pasi A. Jänne, Dong‐Wan Kim et al.|New England Journal of Medicine|2013

Cited by 3.4k

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Geoffrey R. Oxnard, Cloud P. Paweletz et al.|Nature Medicine|2015

Cited by 1.5k